$222.82
1.05% today
NYSE, Dec 11, 09:15 pm CET
ISIN
US00287Y1091
Symbol
ABBV

AbbVie Stock price

$225.18
+6.47 2.96% 1M
+35.68 18.83% 6M
+47.48 26.72% YTD
+49.51 28.18% 1Y
+59.86 36.21% 3Y
+117.69 109.49% 5Y
+169.40 303.69% 10Y
+190.18 543.37% 20Y
NYSE, Closing price Wed, Dec 10 2025
+2.19 0.98%
ISIN
US00287Y1091
Symbol
ABBV
Industry

New AI Insights on AbbVie Insights AI Insights on AbbVie

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$398.0b
Enterprise Value
$461.1b
Net debt
$63.1b
Cash
$5.7b
Shares outstanding
1.8b
Valuation (TTM | estimate)
P/E
170.6 | 20.7
P/S
6.7 | 6.4
EV/Sales
7.7 | 7.4
EV/FCF
23.4
P/B
negative
Dividends
DPS
$6.65
Yield 1Y | 5Y
3.0% | 3.8%
Growth 1Y | 5Y
5.7% | 6.6%
Payout 1Y | 3Y
263.2% | 153.2%
Increased
14 Years
Financials (TTM | estimate)
Revenue
$59.6b | $62.2b
EBITDA
$28.0b | $29.0b
EBIT
$19.7b | $27.7b
Net Income
$2.3b | $19.2b
Free Cash Flow
$19.7b
Growth (TTM | estimate)
Revenue
7.4% | 10.4%
EBITDA
17.3% | 16.6%
EBIT
27.4% | 68.1%
Net Income
-53.8% | 352.7%
Free Cash Flow
26.0%
Margin (TTM | estimate)
Gross
71.2%
EBITDA
46.9% | 46.7%
EBIT
33.1%
Net
3.9% | 30.9%
Free Cash Flow
33.0%
Financial Health
Equity Ratio
2.5%
Return on Equity
127.5%
ROCE
20.9%
ROIC
-
Debt/Equity
-26.0
More
EPS
$1.3
FCF per Share
$11.1
Short interest
1.1%
Employees
55k
Rev per Employee
$1.0m
Show more

Is AbbVie a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

AbbVie Stock Analysis

Unlock Scores for Free

Analyst Opinions

38 Analysts have issued a AbbVie forecast:

26x Buy
68%
12x Hold
32%

Analyst Opinions

38 Analysts have issued a AbbVie forecast:

Buy
68%
Hold
32%

Financial data from AbbVie

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
59,644 59,644
7% 7%
100%
- Direct Costs 17,201 17,201
5% 5%
29%
42,443 42,443
14% 14%
71%
- Selling and Administrative Expenses 13,970 13,970
0% 0%
23%
- Research and Development Expense 8,791 8,791
11% 11%
15%
27,967 27,967
17% 17%
47%
- Depreciation and Amortization 8,254 8,254
1% 1%
14%
EBIT (Operating Income) EBIT 19,713 19,713
27% 27%
33%
Net Profit 2,348 2,348
54% 54%
4%

In millions USD.

Don't miss a Thing! We will send you all news about AbbVie directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbbVie Stock News

Positive
The Motley Fool
about 5 hours ago
Some valuation metrics suggest that AbbVie is a cheap stock. The company's growth prospects through 2030 look attractive.
Positive
Seeking Alpha
about 20 hours ago
AbbVie earns a Strong Buy rating, driven by exceptional execution post-Humira patent cliff and robust 2025 share price outperformance. Skyrizi and Rinvoq are rapidly replacing Humira, delivering 47% and 35% YoY growth in Q3 2025, with patent protection into the 2030s. ABBV's business mix is diversified, with immunology and neuroscience segments together driving double-digit revenue growth and s...
Positive
24/7 Wall Street
one day ago
Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, policy uncertainties around drug pricing, and a surge in tech-driven gains from the AI boom.
More AbbVie News

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Head office United States
CEO Robert Michael
Employees 55,000
Founded 2011
Website www.abbvie.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today